Defining the critical hurdles in cancer immunotherapy
<p>Abstract</p> <p>Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strate...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMC
2011-12-01
|
| Schriftenreihe: | Journal of Translational Medicine |
| Online-Zugang: | http://www.translational-medicine.com/content/9/1/214 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
